about
Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson's disease modelsFuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine DeficiencyTranslating principles of neural plasticity into research on speech motor control recovery and rehabilitation.Mortality in levodopa-treated Parkinson's disease.Pathomechanisms and compensatory efforts related to Parkinsonian speech.Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disordersVariability in cadence during forced cycling predicts motor improvement in individuals with Parkinson's disease.Transcriptome analysis in a rat model of L-DOPA-induced dyskinesiaParkinson disease: Can a new trial end controversy over when to use levodopa?The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Pramipexole for the treatment of early Parkinson's disease.Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor.Community-based Argentine tango dance program is associated with increased activity participation among individuals with Parkinson's disease.Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatmentStage-dependent loss of cortical gyrification as Parkinson disease "unfolds"A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regionsEffects of dopamine D1 and D2 receptor antagonists on laryngeal neurophysiology in the rat.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.The pedunculopontine nucleus as a target for deep brain stimulation.Safety of rasagiline for the treatment of Parkinson's disease.Rotigotine transdermal patch for the treatment of Parkinson's Disease.Overcoming obstacles in Parkinson's disease.Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients.Is Parkinson's disease truly a prion-like disorder? An appraisal of current evidence.Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.Sensory symptoms in Parkinson's disease: Clinical features, pathophysiology, and treatment.Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial.Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease.Voice- and swallow-related quality of life in idiopathic Parkinson's disease.Social support for physical activity and perceptions of control in early Parkinson's disease.Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease.Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease.Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial DepolarizationLack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.
P2860
Q26775886-33748C7A-1BF2-42DA-B2CE-47311E3EAA0EQ28554723-017F3F42-9581-4AA0-859E-F1666A2E8C2CQ28754738-3B78F040-236B-4C22-8EBB-9ABF39E9A2C3Q30414368-5A42FDCC-BF39-4A18-AA23-55C529885D95Q30446173-92F90DB0-EC27-4E2F-8B31-3AD35435650BQ33906026-03FAA5ED-C956-4CE4-9614-2828AF0704E0Q34069887-69B275B1-ECA1-484F-B7F1-6DD59D29708CQ34400095-AA12CF56-DCC0-4036-B4EF-55E5D070A57BQ34434096-0073297B-7F46-4DAB-A55B-E0AF6CC2E41CQ34512544-6C366103-7ED1-4CE4-A4DC-8B65181E39DFQ34630735-B680C253-FEA9-4BF4-98C8-3DE8425439F0Q35070472-B8F79475-2B8F-4F5B-B0A7-8BC54446E4B4Q35615188-FD0BF0EE-BAF9-4F6E-ABD9-79D36B6FB5ACQ36569450-A530403E-9AFD-495F-963E-EFA1008A2474Q36578455-6874A8A0-C07F-4B04-8228-732FFAAE5669Q36763365-AEF0E098-D767-49D5-AB39-AB016356E5DCQ36808111-5572C335-0497-4601-9DC6-3E9003799140Q36818525-0147AB83-8D3C-4B77-A844-D9940EC7AFEBQ37298742-5957F3F6-2A53-464B-9F29-A8EE4D895F4AQ37776519-24377654-0361-474B-9019-B9A0143F46DAQ37824831-050A4568-31B7-4350-9074-86267757432EQ37859776-2C550CE5-B98C-4A76-A95C-F9CFC47A9915Q37982789-8BA57A95-3045-4B7C-A497-4CD34EC1A53AQ38056875-2F53113D-6118-416A-A337-F3A20D905EB3Q38189113-245C5183-245A-4449-9705-1D94FC158367Q38344903-DEC5926A-A74E-40B6-B2E9-03C51C485333Q38439307-0EC48463-044C-455F-85F2-A57C210665C6Q38497529-94224E1D-F45A-4823-A6EF-15982EBA6D37Q38762926-429E9D20-FB08-4A19-A4E8-C934194B6F38Q39098639-9C6A78B5-57D3-4E41-B9BA-ABB98CD62B13Q39302042-BC54A290-31EA-44DA-859D-1409BF48FB61Q39349950-0890B8B3-ABC6-4870-8FAE-03182AF13C64Q39436892-46F1E5D3-CBD4-4918-8272-C83C290169E1Q39550934-924BA05D-32E1-49AB-938A-244D266B0B4EQ39975732-BD4A0EEC-E5E9-4BAF-B7B1-2A45910F88CFQ41113531-C9B9D269-9A2E-4472-9861-7EA90A1D1893Q41526736-4B8AABF8-41EE-426F-B4FC-67A663812E3FQ41626128-569342E2-F0A5-42D0-BFA0-818A8ACD6B72Q42290109-CD1E8570-F3AE-4C72-9D7E-B86347BA4F29Q42800140-9254859E-5A89-412C-B7EA-8D5675E5DF1A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Limitations of current Parkinson's disease therapy.
@ast
Limitations of current Parkinson's disease therapy.
@en
Limitations of current Parkinson's disease therapy.
@nl
type
label
Limitations of current Parkinson's disease therapy.
@ast
Limitations of current Parkinson's disease therapy.
@en
Limitations of current Parkinson's disease therapy.
@nl
prefLabel
Limitations of current Parkinson's disease therapy.
@ast
Limitations of current Parkinson's disease therapy.
@en
Limitations of current Parkinson's disease therapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Limitations of current Parkinson's disease therapy.
@en
P2093
Fabienne Ory
Joaquim J Ferreira
Pierre Payoux
P2860
P304
S3-12; discussion S12-5
P356
10.1002/ANA.10513
P478
53 Suppl 3
P577
2003-01-01T00:00:00Z